Discovering Topoisomerase I: A Potential Drug Target and Biomarker

Target Name: TOP1

NCBI ID: G7150

TOP1

Discovering Topoisomerase I: A Potential Drug Target and Biomarker

Topoisomerase I (TOPI) is a enzyme involved in the repair of DNA double-strands, which is crucial for cellular growth, development, and survival. The protein encoded by the topoisomerase I gene has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, targeting this enzyme has become an attractive strategy for developing new treatments. In this article, we will explore the potential of topoisomerase I as a drug target and biomarker.

The Discovery of Topoisomerase I as a Drug Target

TOPI has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. The protein has four distinct subunits, each with a distinct function in DNA double-strand repair. The subunit responsible for the catalytic activity of TOPI, subunit A, has been shown to interact with various drug molecules, including small molecules, peptides, and nucleic acids.

One of the most promising drug targets associated with TOPI is the inhibition of its catalytic activity by small molecules. This can lead to the inhibition of cellular metabolism and growth, which can be detrimental for the survival of cancer cells. Several studies have demonstrated the effectiveness of inhibitors of TOPI catalytic activity in various cellular models, including cancer cells, suggesting that these compounds may have a therapeutic potential against cancer.

Another potential mechanism by whichTOPI can be targeted is its role in the regulation of cellular apoptosis. In cancer cells, the loss of DNA double-strands can lead to the regulation of apoptosis, which is a critical mechanism for cell death. However, in some cancer cells, the regulation of apoptosis may be disrupted, leading to the survival and proliferation of these cells.

TOPI has also been shown to play a role in the regulation of cellular aging. The protein has been shown to interact with several transcription factors, including activator protein 1 (AP-1), which is involved in the regulation of cellular aging. In addition,TOPI has been shown to promote the expression of genes involved in cellular stress response, suggesting a role in the regulation of cellular stress.

The Discovery of Topoisomerase I as a Biomarker

TOPI has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein has been shown to be expressed in various tissues and has been used as a biomarker for several diseases, including cancer.

In cancer,TOPI has been shown to be expressed in various tissues, including the brain, lung, and liver. Studies have also demonstrated the presence ofTOPI in various types of cancer, including neurobladder cancer, breast cancer, and colorectal cancer. These findings suggest thatTOPI may be a useful biomarker for the diagnosis and prognosis of cancer.

In neurodegenerative diseases,TOPI has been shown to be expressed in the brain and other tissues. Studies have demonstrated the role ofTOPI in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These findings suggest thatTOPI may be a potential biomarker for the diagnosis and treatment of neurodegenerative diseases.

In autoimmune disorders,TOPI has been shown to be expressed in various tissues, including the gut and Peyer's patches. Studies have also demonstrated the role ofTOPI in the regulation of autoimmune disorders, including rheumatoid arthritis and ulcerative colitis. These findings suggest thatTOPI may be a potential biomarker for the diagnosis and treatment of autoimmune disorders.

Conclusion

In conclusion,TOPI is a protein that has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and involvement in various cellular processes make it an attractive target for drug development. The inhibition ofTOPI catalytic activity has been shown to be effective in various cellular models, including cancer cells, suggesting that these compounds may have a therapeutic potential against cancer. Additionally,TOPI has also been shown to play

Protein Name: DNA Topoisomerase I

Functions: Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the BMAL1 promoter

The "TOP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets